Overview

Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

Status:
Active, not recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Investigating potential of controlling brain metastases in patients with EGFR positive NSCLC.
Phase:
Phase 1
Details
Lead Sponsor:
Case Comprehensive Cancer Center
Treatments:
Osimertinib